TABLE 2.

“High-confidence drug resistance-conferring mutations” ^a identified in minority variants from specimens with a single M. tuberculosis strain (N = 1,648)

Strain ID	pDST profile	Majority drug-resistant variant	Minority drug-resistant variant						Predicted MDR c (Y/N)
			Mutation	POS	Nucleotide change	Read depth	AF (%)	Predicted DR b
20-002-0186	INH-R, RIF-S	fabG1 -15 c > t	rpoB_H445N	761139	C to A	70	11.4	RR	Y
18-1773-0451	S	S	rpoB_H445N	761139	C to A	83	12	RR	N
17-3391-0013	S	S	rpoB_H445N	761139	C to A	97	6.2	RR	N
20-002-0411	S	S	rpoB_H445N	761139	C to A	73	5.5	RR	N
20-002-0197D1	S	S	katG_S315T	2155168	C to G	57	8.8	INH-R	N
21-002-0305	S	S	katG_W328L	2155129	C to A	256	3.5	INH-R	N
21-002-0328	S	S	katG_W328L	2155129	C to A	135	3.7	INH-R	N
21-002-0252D1	S	S	katG_W328L	2155129	C to A	168	4.2	INH-R	N
21-002-0252D1	S	S	pncA_G97C	2288953	C to A	175	3.4	PZA-R	N
17-3391-0018	S	S	pncA_V180G	2288703	A to C	91	11	PZA-R	N
21-002-0237	S	S	pncA_A146T	2288806	C to T	255	6.7	PZA-R	N

^a Group 1 (“Assoc W R”) drug-resistant variants, as in 2021 WHO Catalogue (23, 24).

^b Based on the detection of mutations classified as group 1 (associated with resistance) in the WHO catalogue (23, 24).

^c Minority variants with genotypic rifampicin resistance detected in isoniazid resistant strain.